Skip to content

In-Office Clinical Study of the Solo+ TTD

Pivotal In-Office Clinical Study of the Solo+ Tympanostomy Tube Device

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05741333
Acronym
VENTY
Enrollment
66
Registered
2023-02-23
Start date
2023-03-30
Completion date
2028-03-01
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ear Infection, Otitis Media

Brief summary

The objective of this study is to evaluate the safety and effectiveness of the Solo+ Tympanostomy Tube Device (Solo+ TTD) for the placement of tympanostomy tubes in paediatric patients undergoing a tympanostomy procedure.

Detailed description

The study will be a multi-site, prospective, treatment-only study to gather safety and effectiveness data on the use of the Solo+ TTD in-office with topical anesthesia in children aged ≥6 months to \<13 years.

Interventions

The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.

Sponsors

AventaMed DAC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 13 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged ≥6 months to \<13 years * Planned tympanostomy tube insertion * Patient is able to commit to the follow-up visits and assessments

Exclusion criteria

* Anatomy that precludes sufficient visualization of the tympanic membrane * Anatomy that precludes safe access to the tympanic membrane and safe use of the Solo+ TTD * Narrow ear canals * Congenital or craniofacial abnormalities affecting the ear * No baseline audiometry or tympanometry * Familial history of insensitivity to anesthetic components * Patient unable to remain still or is unsuitable for protective stabilization to undergo an in-office procedure

Design outcomes

Primary

MeasureTime frameDescription
Procedure SuccessIntra-operativePercentage of subjects in which the Solo+ TTD tympanostomy tube is inserted in all indicated ears
Rate of Adverse Events24 monthsIncidence and nature of device- or procedure-related adverse events

Countries

United States

Contacts

STUDY_CHAIRMatija Daniel

Queen's Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026